NCT01687309View on ClinicalTrials.gov

A Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single and Repeat Doses of GSK2586184 and the Effect of Food and Gender

PHASE1CompletedINTERVENTIONAL
Enrollment

19

Participants

Timeline

Start Date

April 30, 2012

Primary Completion Date

July 31, 2012

Study Completion Date

July 31, 2012

Conditions
Systemic Lupus Erythematosus
Interventions
DRUG

GSK2586184 800mg single and repeat dose

GSK2586184 800mg single dose and then twice daily dosing for 13 days

DRUG

Placebo-to-match GSK2586184

Placebo-to-match GSK2586184

OTHER

GSK2586184 single dose taken with food

GSK2586184 single dose taken with FDA approved high fat, high calorie breakfast

OTHER

GSK2586184 single dose taken without food

GSK2586184 single dose taken in a fasted state

Trial Locations (1)

2060

GSK Investigational Site, Antwerp

Sponsors

Lead Sponsor

GlaxoSmithKline
All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY

NCT01687309 - A Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single and Repeat Doses of GSK2586184 and the Effect of Food and Gender | Biotech Hunter | Biotech Hunter